ArticleCancer research2026
TENT5A Maintains MYC mRNA Stability to Enhance Osteosarcoma Stemness.
Article in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
MYC genomic amplification and pathway activation are associated with aggressive behavior and poor prognosis in osteosarcoma. However, a discordance exists between copy-number gains and transcriptional output from MYC in osteosarcoma, and defining these mechanisms is critical to understanding and intercepting persistent MYC signaling. In this study, we showed that cytoplasmic mRNA poly(A) sustains MYC activation in osteosarcoma. Multiomics profiling and single-cell transcriptomics identified TENT5A, a noncanonical RNA-binding poly(A) polymerase, as selectively upregulated in MYC-activated tumors and enriched in proliferative, stem-like populations. Biochemical and genetic evidence demonstrated that TENT5A directly bound MYC mRNA via its PAP/OAS1 domain, extended its poly(A) tail, and stabilized the transcript, thereby reinforcing MYC-driven stemness and chemoresistance. Gain- and loss-of-function assays, orthotopic xenografts, and patient-derived organoids confirmed that elevated TENT5A enhanced tumor-initiating capacity and reduced chemotherapy sensitivity. Pharmacologic inhibition of TENT5A disrupted MYC mRNA stabilization, shortened poly(A) tails, and reversed chemoresistance in preclinical models. These findings delineate a posttranscriptional RNA stabilization pathway that reconciles the disconnect between MYC genetic alterations and transcriptional activity and nominate the RNA-binding protein TENT5A as a therapeutically tractable target in osteosarcoma. SIGNIFICANCE: Enhanced MYC mRNA stability mediated by TENT5A-induced poly(A) elongation supports cancer stem cell maintenance in osteosarcoma, highlighting TENT5A inhibition as a potential strategy to block MYC activity in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.